FTSE MIB
33.980,10 +350,89 (+1,04%) Dow Jones
38.675,68 +449,98 (+1,18%) Nasdaq
16.156,33 +315,33 (+1,99%) Nikkei 225
38.236,07 -38,03 (-0,10%) Petrolio
78,93 +0,82 (+1,05%) Bitcoin EUR
60.370,75 +1.220,08 (+2,06%)
Takeda Pharmaceutical Company Limited (TKPHF)
| Chiusura precedente | 26,62 |
| Aperto | 27,10 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 26,62 - 26,62 |
| Intervallo di 52 settimane | 25,04 - 34,47 |
| Volume | |
| Media Volume | 6.201 |
| Capitalizzazione | 42,281B |
| Beta (5 anni mensile) | 0,54 |
| Rapporto PE (ttm) | 36,97 |
| EPS (ttm) | 0,72 |
| Prossima data utili | 09 mag 2024 |
| Rendimento e dividendo (futuro) | 1,24 (4,67%) |
| Data ex dividendo | 28 mar 2024 |
| Stima target 1A | N/D |
GlobeNewswireHUTCHMED Announces Submission of New Drug Application for Fruquintinib for Previously Treated Metastatic Colorectal Cancer in Japan
— Third major market authorization application based on data from the FRESCO-2 global Phase III trial —HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Sept. 29, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (Nasdaq/AIM:HCM, HKEX:13) (“HUTCHMED”) today announced that Takeda (TSE:4502/NYSE:TAK) has submitted a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare (“MHLW”) in Japan for the approval of fruquintinib for the treatment of adult patients with previously
- GlobeNewswire
HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet
— Publication shows FRESCO-2 demonstrated treatment with fruquintinib reduced the risk of death by 34% in previously treated metastatic colorectal cancer (0.66 HR) — — Data support regulatory submissions in the U.S., Europe and Japan during 2023 — HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J. and OSAKA, Japan and CAMBRIDGE, Mass., June 15, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) and Takeda (TSE:4502, NYSE:TAK) today announced that results
